Krsnaa Diagnostics Appoints New Directors, Interim CFO; Several Directors to Exit
Krsnaa Diagnostics appointed Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors from April 25, 2026, for two years. Mr. Chetan Desai was re-appointed as Independent Director for five years from April 25, 2026. Mr. Chandra Prakash Singh is the new Interim CFO from April 17, 2026. Ms. Pallavi Bhatevara, Mr. Rajiva Ranjan Verma, and Ms. Chhaya Palrecha will exit their roles by April 25, 2026.
The appointment of new directors and an interim CFO, alongside the departure of existing board members, represents a significant shift in the company's leadership. This could influence strategic direction and operational oversight, thus having a medium-term impact.
The announcement details changes in management and board composition, including appointments and cessations. While these changes aim to strengthen governance, the net impact on the company's performance is neutral at this stage.
Krsnaa Diagnostics Limited announced significant changes in its leadership and governance framework following a Board of Directors meeting held on April 17, 2026.
Key appointments approved include Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Additional Directors (Independent Directors) for a term of two years, effective April 25, 2026, to April 24, 2028. Mr. Chetan Desai has been re-appointed as an Independent Director for a subsequent term of five years, commencing April 25, 2026, up to April 24, 2031. Mr. Chandra Prakash Singh has been appointed as the Interim Chief Financial Officer (Interim CFO), designated as Key Managerial Personnel (KMP), effective April 17, 2026, to serve until a new CFO is appointed.
Concurrently, the company noted the completion of tenure for several directors. Ms. Pallavi Bhatevara will cease to be a Whole-time Director effective close of business hours on April 25, 2026. Mr. Rajiva Ranjan Verma and Ms. Chhaya Palrecha will cease to be Independent Directors effective close of business hours on April 24, 2026, upon completion of their respective tenures.
Following these changes, the Board of Directors has approved the reconstitution of various committees, including the Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee, Stakeholders Relationship Committee, and Risk Management Committee, effective April 25, 2026. The meeting commenced at 12:00 Hrs (IST) and concluded at 15:50 Hrs (IST).
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.